Thymagen
Immune & Anti-InflammatoryAlso known as: Glu-Trp, EW, L-Glutamyl-L-Tryptophan, Thymogen, Thymus Bioregulator
Mechanism
Thymagen is a dipeptide bioregulator designed to restore thymus gland function and reverse age-related immune decline (immunosenescence). The thymus is the organ where T-cells mature, and it shrinks dramatically with age — a major reason older adults have weaker immune systems. Thymagen helps reactivate thymic function, promoting T-cell maturation and improving overall immune competence. It differs from Thymalin (another thymic peptide) by being a smaller, synthetic molecule rather than an extract.
Technical detail
Synthetic dipeptide (L-glutamyl-L-tryptophan, Glu-Trp) developed by Khavinson as a thymus-specific bioregulator. Molecular weight 333.34 g/mol. Modulates intracellular second-messenger pools, particularly cyclic nucleotide systems (cAMP/cGMP balance) in lymphoid cells. Activates T-cell differentiation, enhances T-cell recognition of peptide-MHC complexes, and modulates cytokine production (IL-2, interferon). Experimental applications include: second-messenger signaling studies evaluating cyclic nucleotide pools and downstream kinase signaling; immune differentiation models examining T-lymphocyte precursor maturation and phenotypic transitions; and cytokine/interferon pathway assays. Registered in Russia as the pharmaceutical Thymogen for immune restoration.
Effects
IMMUNE: Primary target system. Designed to restore thymic function and reverse immunosenescence (age-related immune decline). The thymus involutes dramatically after puberty — by age 50, ~80% of thymic tissue is replaced by fat, reducing naïve T-cell output and weakening adaptive immunity. Thymagen targets this specific problem. Modulates intracellular cAMP/cGMP balance in lymphoid cells — a key second messenger system that controls immune cell activation and differentiation. Activates T-cell differentiation — promotes maturation of T-lymphocyte precursors into functional effector cells. Enhances T-cell recognition of peptide-MHC complexes — improving antigen-specific immune responses. Modulates cytokine production: increases IL-2 (T-cell growth factor) and interferon (antiviral/anti-tumor) production from blood lymphocytes. Registered in Russia as pharmaceutical Thymogen — decades of clinical use data in Russian healthcare system. Differs from Thymalin: Thymagen is a synthetic dipeptide; Thymalin is an extract from calf thymus containing a mixture of peptides. Thymagen is more defined and reproducible. NEUROLOGICAL: Tryptophan (one of the two amino acids) is a serotonin precursor, but no direct CNS effects documented at bioregulator doses. ENDOCRINE: Thymic peptides interact with the neuroendocrine-immune axis — thymus function influences growth hormone, prolactin, and cortisol regulation (bidirectional communication, well-established in psychoneuroimmunology). CARDIOVASCULAR: No direct cardiovascular effects. Improved immune function may reduce chronic inflammation that contributes to cardiovascular disease. METABOLIC: No direct metabolic effects. Immune restoration may improve metabolic health by reducing inflammation-driven insulin resistance. Tier 3: Russian pharmaceutical with extensive clinical use. Practitioners report improved resistance to respiratory infections, faster recovery from illness, and normalization of lymphocyte counts within 2-4 weeks. Particularly valued for elderly patients with recurrent infections.
Practitioner Guide
DOSING TIPS: Two main routes: (1) Injectable — 10-20mg subcutaneous daily for 10-30 days. (2) Intranasal — nasal spray formulation (Thymogen nasal spray is a registered pharmaceutical in Russia). Oral capsules less common due to dipeptide's GI degradation susceptibility. Start with a 10-day injectable course and assess response. RECONSTITUTION: Lyophilized powder — reconstitute with bacteriostatic water. For 20mg vial: add 1-2mL BAC water. INJECTION SITE: Subcutaneous — abdominal fat pad or thigh. TIMING: Morning administration preferred — immune system is most active during waking hours. SUPPLEMENT SYNERGIES: Stack with Thymalin for comprehensive thymic support (Thymagen for direct immune cell modulation + Thymalin for thymic microenvironment restoration). Combine with Thymosin Alpha-1 for enhanced T-cell activation (different mechanism — Thymosin Alpha-1 is a larger peptide acting on dendritic cells and TLR pathways). Zinc (30-50mg/day) — essential for thymic hormone production and T-cell development. Vitamin D3 (5000 IU/day) — critical immunomodulator. Vitamin C (1-2g/day) — supports immune cell function. Selenium (200mcg/day) — required for T-cell proliferation. CYCLING: Course-based — 10-30 days on, 3-6 month break. 2-3 courses per year, timed with seasonal infection peaks (pre-winter, pre-spring). STACKING: Immune restoration: Thymagen + Thymalin + Thymosin Alpha-1. Anti-aging immune: Thymagen + Epithalon + Endoluten. Infection prevention: Thymagen + LL-37 + Vitamin D3. Post-illness recovery: Thymagen + BPC-157 + Glutathione. CONTRAINDICATION NUANCES: Autoimmune diseases — immune stimulation could worsen autoimmune conditions. Use with extreme caution in Hashimoto's, lupus, RA, MS. Patients on immunosuppressants (post-transplant, active autoimmune treatment) — contraindicated. Active cancer — immune stimulation is generally positive for cancer surveillance, but discuss with oncologist. STORAGE: Lyophilized — room temperature or refrigerated. Nasal spray — refrigerate. PATIENT EDUCATION: Your thymus gland — located behind your breastbone — is where T-cells (the immune system's special forces) are trained. It shrinks dramatically with age, which is why older adults get sick more often and respond less to vaccines. Thymagen helps restore thymic function by directly supporting T-cell maturation. It is a registered pharmaceutical in Russia, not just a research peptide. Effects are preventive — best used before flu season or during periods of high infection risk. Track CBC with differential to monitor lymphocyte counts.
Research Summary
TIER 1 (Gold Standard): No Western RCTs exist for Thymagen specifically. Russian pharmaceutical registration as Thymogen provides regulatory-level clinical data (though not accessible via Western databases). TIER 2 (Strong): Khavinson VK & Morozov VG — original publications on thymic peptide bioregulators (Bulletin of Experimental Biology and Medicine, multiple publications). Natural and synthetic thymic peptides as therapeutics for immune dysfunction (ScienceDirect review article). Thymic peptide immunology is well-established — the role of the thymus in T-cell maturation and immunosenescence is Tier 1 immunology. TIER 3 (Moderate): Russian post-marketing surveillance data spanning decades. Clinical use in Russian healthcare system for immunodeficiency states and recurrent infections. Practitioner protocols from European anti-aging and immunology clinics. Community reports of improved infection resistance. International data: widely used in CIS countries as a registered pharmaceutical. KEY FINDINGS: (1) Thymic peptides for immune restoration have a strong biological rationale. (2) Thymagen is a registered pharmaceutical in Russia with decades of use. (3) Mechanism via cAMP/cGMP modulation is pharmacologically plausible. (4) No Western clinical validation. (5) Dipeptide size raises bioavailability questions for oral use. GAPS: Western clinical trials. Pharmacokinetic data. Head-to-head comparison with Thymalin and Thymosin Alpha-1. Bioavailability by route. Long-term immune outcomes. ACTIVE TRIALS: None registered on ClinicalTrials.gov.